BioWorld

April 19, 2005

View Archived Issues

Fibrillex Misses; Neurochem Stock Drops By 28 Percent

While Fibrillex demonstrated a positive trend in AA amyloidosis patients, a Phase II/III trial missed its primary endpoint, causing Neurochem Inc.'s stock plunge of 28.5 percent. (BioWorld Today) Read More

CV Therapeutics Reports Good Ranexa Data From Phase III

Read More

Nuvelo Begins Phase III Trial Of Alfimeprase In 'Leg Attack'

Read More

Onyx, Bayer Offer Sorafenib To All Pivotal Trial Patients

Read More

AACR News

Read More

Other News To Note

Read More